InsiderTrades

Form 4 for AMGN Amgen

Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0000318154-26-000023 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-03-06 2026-03-04 AMGN Bradway Robert A COB, CEO, Pres, Dir M - OptEx $156.35 +119.8K 576.9K +26% +$18.73M
D 2026-03-06 2026-03-04 AMGN Bradway Robert A COB, CEO, Pres, Dir F - Tax $379.27 -84.3K 492.6K -15% -$31.97M
D 2026-03-06 2026-03-04 AMGN Bradway Robert A COB, CEO, Pres, Dir M - OptEx $0.00 -119.8K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-03-04 M A 119,782 $156.35 576,928 D — — (F1) Non-market exercise of a total of 119,872 stock options expiring May 3, 2026 wherein 84,285 shares, in the aggregate, issuable pursuant to the exercise of these options were withheld by the Company to cover the option exercise price and tax withholding, with the remaining shares delivered to the reporting person.
2 Common Common Stock 2026-03-04 F D 84,285 $379.27 492,643 D — — (F2) These shares include 2,414 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
3 Derivative Nqso (Right to Buy) 2026-03-04 M D 119,782 $0.00 0 D $156.35 · 2018-05-03 to 2026-05-03 119,782 Common Stock